Volume 30, Number 6—June 2024
Research
SARS-CoV-2 Disease Severity and Cycle Threshold Values in Children Infected during Pre-Delta, Delta, and Omicron Periods, Colorado, USA, 2021–2022
Laura Bankers
, Shannon C. O’Brien, Diana M. Tapay, Erin Ho, Isaac Armistead, Alexis Burakoff, Samuel R. Dominguez, and Shannon R. Matzinger
, Shannon C. O’Brien, Diana M. Tapay, Erin Ho, Isaac Armistead, Alexis Burakoff, Samuel R. Dominguez, and Shannon R. Matzinger
Table 2
Number of pediatric COVID-19 inpatients by SARS-CoV-2 variant period and potential indicator of disease severity during pre-Delta, Delta, and Omicron periods, Colorado, USA, January 2021–January 2022*
| Indicator of disease severity† | No. (%, 95% CI] |
||||
|---|---|---|---|---|---|
| Total, n = 395 | Pre-Delta, n = 69 | Delta, n = 86 | Omicron, n = 210 | p value‡ | |
| Symptomatic | 343 (86.8, 83.1–90.0) | 52 (75.4, 63.5–84.9) | 82 (95.3, 88.5–98.7) | 209 (99.5, 97.4–99.9) | <0.0001 |
| Hospitalized | 395 (100, 99.1–100) | 69 (100, 94.8–100) | 86 (100, 95.8–100) | 210 (100, 98.3–100) | 1.0 |
| PICU admission | 94 (23.8, 19.7–28.3) | 12 (18.8, 9.3–28.4) | 34 (39.5, 29.2–50.7) | 48 (22.9, 17.4–29.1) | 0.002 |
| Received any oxygen support | 217 (54.9, 49.9–59.9) | 29 (42.0, 30.2–54.5) | 57 (66.3, 55.3–76.1) | 131 (62.4, 55.5–69.0) | 0.04 |
*PICU, pediatric intensive care unit. †All indicators of disease severity included here were considered to be a result of COVID-19 illness. ‡p values were obtained from χ2 test of patient characteristics across the 3 variant periods.
Page created: April 08, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.